IRX Therapeutics, Inc. — Form D/A
IRX Therapeutics, Inc. of New York, NY, a company, filed a Form D amendment with the SEC on 2015-08-17. The offering totals $40.6M, of which $40.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2015-08-17
- Form: D/A
- Accession: 0001411920-15-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $40.6M
- Amount sold: $40.6M
- Investors: 230
- Date of first sale: 2014-12-31
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-232269
Issuer
- Name: IRX Therapeutics, Inc.
- CIK: 0001411920
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 654 MADISON AVENUE, New York, NY, 10065
- Phone: 212-582-1199
Officers, directors & promoters (21)
| Name | Role | Location |
|---|
| John T Spitznagel | Director | New York, NY |
| David H Deming | Director | King of Prussia, PA |
| Jeffrey Hwang | Executive Officer | New York, NY |
| Frank J Loverro | Director | New York, NY |
| John W Hadden II | Director | Sparta, NJ |
| John W Hadden II | Executive Officer | Sparta, NJ |
| Charles R Cherington | Director | Houston, TX |
| George P Denny III | Director | Houston, TX |
| Mark W Leuchtenberger | Director | New York, NY |
| Mark W Leuchtenberger | Executive Officer | New York, NY |
| John D Halpern | Director | New York, NY |
| Ferid D Murad | Director | New York, NY |
| Lawrence M Wolf | Director | New York, NY |
| Edmund W Truell | Director | New York, NY |
| Zygmund P Roth | Executive Officer | New York, NY |
| Monil W Shah | Executive Officer | New York, NY |
| Curtis P Robb | Executive Officer | New York, NY |
| John W Hadden | Director | New York, NY |
| Ferid W Murad | Director | New York, NY |
| Howard H Stevenson | Director | New York, NY |
| Jeffrey Hwuang | Executive Officer | New York, NY |
Other filings by this issuer (9)
More